胸腺上皮肿瘤中程序性死亡蛋白1及其配体的临床研究进展  

Research progression of PD-1/PD-L1 in thymic epithelial tumors

作　　者：王凯瑞 郭丽[1] 梁永峰 李涛 Wang Kairui;Guo Li;Liang Yongfeng;Li Tao(Graduate School of Ningxia Medical University,Ningxia Yinchuan 750004,China;Department of Surgical Oncology,Tumor Hospital,General Hospital of Ningxia Medical University,Ningxia Yinchuan 750004,China)

机构地区：[1]宁夏医科大学研究生院,宁夏银川750004 [2]宁夏医科大学总医院肿瘤医院肿瘤外科,宁夏银川750004

出　　处：《现代肿瘤医学》2020年第9期1580-1582,共3页Journal of Modern Oncology

基　　金：国家自然科学基金(编号:81660500);宁夏医科大学国内一流建设学科临床医学项目资助(编号:NXYLXK2017A05)。

摘　　要：近年来,随着免疫治疗及肿瘤微环境概念的广泛普及,许多肿瘤靶向位点被人们关注并投以大量的实验研究。程序性死亡蛋白1及其配体(PD-1/PD-L1)作为目前最热门的一个免疫靶点通路,其抑制剂已经应用于多种恶性肿瘤的治疗当中。胸腺上皮肿瘤(TETs)是一种较为少见的肿瘤,目前已有证据表明PD-L1在TETs中存在高表达水平并且其与疾病的预后相关,因此本文针对PD-1/PD-L1在TETs中的临床研究进展作一综述。Recently,with the widespread popularity of immunotherapy and the concept of tumor microenvironment,many tumor targeting sites have attracted attention and a large number of experimental studies have been conducted.As one of the most popular tumor immune signaling pathway,inhibitor of PD-1/PD-L1 has been used in the treatment of a variety of malignant tumors.TETs is a relatively rare tumor.Currently,there are evidences that PD-L1 has a high expression level in TETs and is related to the prognosis of the disease.Therefore,the aim of this paper is to summarize the research progression of PD-1/PD-L1 in TETs.

关 键 词：胸腺上皮肿瘤 程序性死亡蛋白1 程序性死亡蛋白1配体 免疫治疗 

分 类 号：R730.51[医药卫生—肿瘤]